CEO.CA SEDI filings for

SEDI Insider filing browser

Date	Issuer	Insider	Transaction	Amount	New Balance ⓘ The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2024-03-08 17:46 Tx date 2024-03-04	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-9,000 vol	201,000
Filed 2024-03-08 17:38 Tx date 2024-03-04	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-35,000 vol	643,021
Filed 2024-03-08 17:27 Tx date 2024-03-04	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$16,666 +16,666 vol $1.00 each	247,485
Filed 2024-03-08 17:21 Tx date 2024-03-04	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-16,666 -16,666 vol $1.00 each	20,000
Filed 2024-03-07 16:31 Tx date 2024-03-07	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$7,800 +15,000 vol $0.52 each	115,000
Filed 2024-03-07 11:49 Tx date 2024-03-07	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$10,000 +20,000 vol $0.50 each	1,003,296
Filed 2024-03-06 11:38 Tx date 2024-03-06	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$9,600 +24,000 vol $0.40 each	254,819
Filed 2024-01-13 16:23 Tx date 2023-10-21	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 52 - Expiration of options	-7,500 vol	46,251
Filed 2024-01-13 16:19 Tx date 2023-10-21	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 52 - Expiration of options	-7,500 vol	65,000
Filed 2024-01-13 16:11 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$12,482 +11,666 vol $1.07 each	38,334
Filed 2024-01-13 16:10 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-12,482.62 -11,666 vol $1.07 each	1,666
Filed 2024-01-13 16:07 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$12,482 +11,666 vol $1.07 each	38,334
Filed 2024-01-13 16:06 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-12,482.62 -11,666 vol $1.07 each	1,666
Filed 2024-01-13 16:04 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$14,267 +13,334 vol $1.07 each	333,334
Filed 2024-01-13 16:03 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-14,267.38 -13,334 vol $1.07 each	1,666
Filed 2024-01-13 16:00 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$42,800 +40,000 vol $1.07 each	95,334
Filed 2024-01-13 15:59 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-42,800 -40,000 vol $1.07 each	1,666
Filed 2024-01-13 15:56 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$14,267 +13,334 vol $1.07 each	185,136
Filed 2024-01-13 15:55 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-14,267.38 -13,334 vol $1.07 each	1,666
Filed 2024-01-13 15:48 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$12,482 +11,666 vol $1.07 each	202,819
Filed 2024-01-13 15:47 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-12,482.62 -11,666 vol $1.07 each	71,666
Filed 2024-01-13 15:43 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Common Shares 57 - Exercise of rights	$22,238 +20,784 vol $1.07 each	123,209
Filed 2024-01-13 15:42 Tx date 2024-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	$-22,238.88 -20,784 vol $1.07 each	75,684
Filed 2023-11-18 15:28 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$5,200 +5,000 vol $1.04 each	191,153
Filed 2023-11-18 15:27 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-5,200 -5,000 vol $1.04 each	83,332
Filed 2023-11-18 15:25 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	26,668
Filed 2023-11-18 15:24 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	13,332
Filed 2023-11-18 15:22 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	26,668
Filed 2023-11-18 15:22 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	13,332
Filed 2023-11-18 15:20 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	320,000
Filed 2023-11-18 15:19 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	15,000
Filed 2023-11-18 15:17 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	55,334
Filed 2023-11-18 15:17 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	41,666
Filed 2023-11-18 15:14 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	171,802
Filed 2023-11-18 15:14 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	15,000
Filed 2023-11-18 15:07 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,733 +1,667 vol $1.04 each	41,700
Filed 2023-11-18 15:07 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,733.68 -1,667 vol $1.04 each	10,000
Filed 2023-11-18 15:03 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Common Shares 57 - Exercise of rights	$3,466 +3,333 vol $1.04 each	102,425
Filed 2023-11-18 15:02 Tx date 2023-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	$-3,466.32 -3,333 vol $1.04 each	96,468
Filed 2023-09-15 18:29 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	20,000
Filed 2023-09-15 18:26 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	20,000
Filed 2023-09-15 18:24 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	40,000
Filed 2023-09-15 18:18 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	20,000
Filed 2023-09-15 18:15 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	53,751
Filed 2023-09-15 18:11 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	72,500
Filed 2023-09-15 18:08 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+36,000 vol	48,000
Filed 2023-09-15 18:05 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+136,000 vol	248,000
Filed 2023-09-15 17:52 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+108,000 vol	210,000
Filed 2023-09-15 17:49 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+108,000 vol	144,000
Filed 2023-09-15 17:45 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Options 50 - Grant of options	+72,000 vol	72,000
Filed 2023-09-15 17:44 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Options 00 - Opening Balance-Initial SEDI Report
Filed 2023-09-15 17:24 Tx date 2023-09-12	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+255,000 vol	678,021
Filed 2023-05-03 13:27 Tx date 2023-05-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$1,799 +3,333 vol $0.54 each	40,033
Filed 2023-05-03 13:27 Tx date 2023-05-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-1,799.82 -3,333 vol $0.54 each	11,667
Filed 2023-05-03 13:23 Tx date 2023-05-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$8,999 +16,666 vol $0.54 each	186,153
Filed 2023-05-03 13:22 Tx date 2023-05-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-8,999.64 -16,666 vol $0.54 each	88,332
Filed 2023-03-06 12:18 Tx date 2023-03-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$8,500 +16,667 vol $0.51 each	169,487
Filed 2023-03-06 12:17 Tx date 2023-03-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-8,500.17 -16,667 vol $0.51 each	104,998
Filed 2023-01-14 16:02 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$6,883 +11,667 vol $0.59 each	25,001
Filed 2023-01-14 16:01 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-6,883.53 -11,667 vol $0.59 each	14,999
Filed 2023-01-14 15:58 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$6,883 +11,667 vol $0.59 each	25,001
Filed 2023-01-14 15:57 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-6,883.53 -11,667 vol $0.59 each	14,999
Filed 2023-01-14 15:54 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$7,866 +13,333 vol $0.59 each	318,333
Filed 2023-01-14 15:53 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-7,866.47 -13,333 vol $0.59 each	16,667
Filed 2023-01-14 15:50 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$7,866 +13,333 vol $0.59 each	170,135
Filed 2023-01-14 15:49 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-7,866.47 -13,333 vol $0.59 each	16,667
Filed 2023-01-14 15:44 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$6,883 +11,667 vol $0.59 each	152,820
Filed 2023-01-14 15:44 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-6,883.53 -11,667 vol $0.59 each	121,665
Filed 2023-01-14 15:39 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 57 - Exercise of rights	$12,261 +20,783 vol $0.59 each	99,092
Filed 2023-01-14 15:37 Tx date 2023-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Restricted Share Units 57 - Exercise of rights	$-12,261.97 -20,783 vol $0.59 each	99,801
Filed 2022-12-16 22:34 Tx date 2022-12-13	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-44,590 -91,000 vol $0.49 each	1,522,976
Filed 2022-12-16 22:33 Tx date 2022-12-12	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-77,910 -159,000 vol $0.49 each	1,613,976
Filed 2022-12-01 22:25 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$22,800 +47,500 vol $0.48 each	68,918
Filed 2022-12-01 22:23 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-22,800 -47,500 vol $0.48 each	110,000
Filed 2022-12-01 22:19 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$2,560 +5,334 vol $0.48 each	305,000
Filed 2022-12-01 22:18 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-2,560.32 -5,334 vol $0.48 each	30,000
Filed 2022-12-01 22:14 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$24,960 +52,000 vol $0.48 each	53,667
Filed 2022-12-01 22:13 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-24,960 -52,000 vol $0.48 each	43,333
Filed 2022-12-01 22:08 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$2,560 +5,334 vol $0.48 each	156,802
Filed 2022-12-01 22:07 Tx date 2022-11-28	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-2,560.32 -5,334 vol $0.48 each	30,000
Filed 2022-11-19 13:20 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	13,334
Filed 2022-11-19 13:19 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	26,666
Filed 2022-11-19 13:15 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	5,000
Filed 2022-11-19 13:13 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 13:11 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	13,334
Filed 2022-11-19 13:08 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	26,666
Filed 2022-11-19 13:02 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	5,000
Filed 2022-11-19 13:01 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:58 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	299,666
Filed 2022-11-19 12:57 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	35,334
Filed 2022-11-19 12:55 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	25,000
Filed 2022-11-19 12:52 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+15,000 vol	325,000
Filed 2022-11-19 12:49 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	1,667
Filed 2022-11-19 12:48 Tx date 2018-03-19	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:48 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	95,333
Filed 2022-11-19 12:45 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	5,000
Filed 2022-11-19 12:44 Tx date 2018-03-19	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:41 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	151,468
Filed 2022-11-19 12:41 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	35,334
Filed 2022-11-19 12:38 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	38,751
Filed 2022-11-19 12:35 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	+5,000 vol	57,500
Filed 2022-11-19 12:29 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$800.16 +1,667 vol $0.48 each	36,700
Filed 2022-11-19 12:28 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-800.16 -1,667 vol $0.48 each	15,000
Filed 2022-11-19 12:24 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+12,000 vol	12,000
Filed 2022-11-19 12:23 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:20 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+42,000 vol	112,000
Filed 2022-11-19 12:10 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+36,000 vol	102,000
Filed 2022-11-19 12:05 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	$2,400 +5,000 vol $0.48 each	127,623
Filed 2022-11-19 12:04 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	$-2,400 -5,000 vol $0.48 each	133,332
Filed 2022-11-19 12:00 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+36,000 vol	36,000
Filed 2022-11-19 11:58 Tx date 2020-05-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 11:54 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Common Shares 57 - Exercise of rights	$1,599 +3,333 vol $0.48 each	78,309
Filed 2022-11-19 11:53 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	$-1,599.84 -3,333 vol $0.48 each	120,584
Filed 2022-11-19 11:46 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+24,000 vol	94,000
Filed 2022-11-19 11:41 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	+85,000 vol	423,021
Filed 2022-11-16 20:05 Tx date 2022-11-16	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,897 +13,530 vol $0.362 each	136,153
Filed 2022-11-16 19:56 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$19,400 +40,000 vol $0.485 each	983,296
Filed 2022-11-16 19:50 Tx date 2022-11-15	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$10,000 +20,000 vol $0.50 each	100,000
Filed 2022-08-19 14:12 Tx date 2022-08-16	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$1,716 +3,300 vol $0.52 each	122,623
Filed 2022-08-19 14:11 Tx date 2022-08-16	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,384 +8,120 vol $0.54 each	119,323
Filed 2022-08-19 14:09 Tx date 2022-08-16	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,335 +8,500 vol $0.51 each	111,203
Filed 2022-07-20 18:50 Tx date 2022-07-15	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-3,100 -5,000 vol $0.62 each	1,772,976
Filed 2022-07-14 21:06 Tx date 2022-02-27	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-4,000 vol	1,750
Filed 2022-07-13 13:50 Tx date 2022-06-16	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 38 - Redemption, retraction, cancellation, repurchase	-8,333 vol	0
Filed 2022-07-13 13:47 Tx date 2022-06-16	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 38 - Redemption, retraction, cancellation, repurchase	-1,750 vol	4,000
Filed 2022-07-12 20:04 Tx date 2022-07-12	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-18,910 -30,500 vol $0.62 each	1,777,976
Filed 2022-07-12 20:04 Tx date 2022-07-11	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-25,730 -41,500 vol $0.62 each	1,808,476
Filed 2022-07-12 20:03 Tx date 2022-07-11	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-12,000 -20,000 vol $0.60 each	1,849,976
Filed 2022-07-12 20:02 Tx date 2022-07-08	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-5,270 -8,500 vol $0.62 each	1,869,976
Filed 2022-07-12 20:01 Tx date 2022-07-08	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-3,111 -5,100 vol $0.61 each	1,878,476
Filed 2022-07-12 20:00 Tx date 2022-07-08	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-9,600 -16,000 vol $0.60 each	1,883,576
Filed 2022-07-12 19:59 Tx date 2022-07-07	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-13,330 -21,500 vol $0.62 each	1,899,576
Filed 2022-07-12 19:47 Tx date 2022-07-08	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$12,400 +20,000 vol $0.62 each	80,000
Filed 2022-07-12 19:24 Tx date 2022-07-12	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$18,600 +30,000 vol $0.62 each	943,296
Filed 2022-07-12 19:17 Tx date 2022-07-11	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$15,190 +24,500 vol $0.62 each	913,296
Filed 2022-07-12 19:16 Tx date 2022-07-11	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,500 +7,500 vol $0.60 each	888,796
Filed 2022-05-10 19:27 Tx date 2022-05-06	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$19,950 +28,500 vol $0.70 each	35,033
Filed 2022-05-05 12:00 Tx date 2022-05-02	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+3,333 vol	6,533
Filed 2022-05-05 11:59 Tx date 2022-05-02	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-3,333 vol	16,667
Filed 2022-05-05 11:55 Tx date 2022-05-02	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+16,667 vol	102,703
Filed 2022-05-05 11:54 Tx date 2022-05-02	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-16,667 vol	138,332
Filed 2022-03-07 14:33 Tx date 2022-03-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+16,667 vol	86,036
Filed 2022-03-07 14:32 Tx date 2022-03-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-16,667 vol	154,999
Filed 2022-01-13 14:10 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+11,667 vol	11,667
Filed 2022-01-13 14:10 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2022-01-13 14:09 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-11,667 vol	28,333
Filed 2022-01-13 14:06 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+11,667 vol	11,667
Filed 2022-01-13 14:04 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2022-01-13 14:03 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-11,667 vol	28,333
Filed 2022-01-13 13:56 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+13,333 vol	297,999
Filed 2022-01-13 13:53 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-13,333 vol	37,001
Filed 2022-01-13 13:50 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+13,333 vol	149,801
Filed 2022-01-13 13:49 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-13,333 vol	37,001
Filed 2022-01-13 13:45 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+11,667 vol	69,369
Filed 2022-01-13 13:44 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-11,667 vol	171,666
Filed 2022-01-13 13:39 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 57 - Exercise of rights	+20,783 vol	74,976
Filed 2022-01-13 13:36 Tx date 2022-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Restricted Share Units 57 - Exercise of rights	-20,783 vol	123,917
Filed 2021-12-01 23:39 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+5,333 vol	284,666
Filed 2021-12-01 23:38 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-5,333 vol	50,334
Filed 2021-12-01 23:35 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+5,333 vol	136,468
Filed 2021-12-01 23:34 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-5,333 vol	50,334
Filed 2021-12-01 23:30 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+5,333 vol	502,360
Filed 2021-12-01 23:29 Tx date 2021-11-29	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-5,333 vol	50,334
Filed 2021-11-19 22:39 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Restricted Share Units 56 - Grant of rights	+20,000 vol	144,700
Filed 2021-11-19 20:54 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+10,000 vol	20,000
Filed 2021-11-19 20:47 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+30,000 vol	245,700
Filed 2021-11-19 20:45 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+30,000 vol	227,700
Filed 2021-11-19 20:42 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+30,000 vol	183,333
Filed 2021-11-19 20:39 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+75,000 vol	1,164,200
Filed 2021-11-19 20:33 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+85,000 vol	1,277,200
Filed 2021-11-19 20:29 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	40,000
Filed 2021-11-19 20:27 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	40,000
Filed 2021-11-19 20:24 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	55,667
Filed 2021-11-19 20:22 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	97,000
Filed 2021-11-19 20:19 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	55,667
Filed 2021-11-19 20:15 Tx date 2021-11-15	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+5,000 vol	55,667
Filed 2021-11-16 14:21 Tx date 2021-11-10	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$45,000 +50,000 vol $0.90 each	497,027
Filed 2021-11-07 18:59 Tx date 2021-11-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$24,385 +25,000 vol $0.98 each	447,027
Filed 2021-11-03 16:59 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$23,265 +23,500 vol $0.99 each	279,333
Filed 2021-11-03 16:58 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,430 +3,500 vol $0.98 each	255,833
Filed 2021-11-03 16:58 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$960.00 +1,000 vol $0.96 each	252,333
Filed 2021-11-03 16:57 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$6,175 +6,500 vol $0.95 each	251,333
Filed 2021-11-03 16:56 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$19,740 +21,000 vol $0.94 each	244,833
Filed 2021-11-03 16:55 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,650 +5,000 vol $0.93 each	223,833
Filed 2021-11-03 16:55 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$2,275 +2,500 vol $0.91 each	218,833
Filed 2021-11-03 16:54 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$22,250 +25,000 vol $0.89 each	216,333
Filed 2021-11-02 15:50 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$2,403 +2,700 vol $0.89 each	3,200
Filed 2021-11-02 15:42 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$435.00 +500 vol $0.87 each	500
Filed 2021-11-02 15:37 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2021-11-02 15:36 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stegic, Ana 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report		10,000
Filed 2021-11-02 11:36 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$14,450 +17,000 vol $0.85 each	1,921,076
Filed 2021-11-02 11:36 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$27,720 +33,000 vol $0.84 each	1,904,076
Filed 2021-11-02 11:33 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$23,500 +25,000 vol $0.94 each	422,027
Filed 2021-11-01 19:37 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$9,999 +13,888 vol $0.72 each	57,702
Filed 2021-11-01 19:27 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$33,320 +34,000 vol $0.98 each	881,296
Filed 2021-11-01 19:26 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$26,600 +28,000 vol $0.95 each	847,296
Filed 2021-11-01 19:25 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,290 +3,500 vol $0.94 each	819,296
Filed 2021-11-01 19:24 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$34,410 +37,000 vol $0.93 each	815,796
Filed 2021-11-01 19:23 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$2,300 +2,500 vol $0.92 each	778,796
Filed 2021-11-01 13:37 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$11,440 +13,000 vol $0.88 each	60,000
Filed 2021-10-13 22:22 Tx date 2021-05-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+16,667 vol	26,471
Filed 2021-10-13 22:21 Tx date 2021-05-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-16,667 vol	153,333
Filed 2021-10-13 22:19 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+50,000 vol	170,000
Filed 2021-10-13 17:19 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+12,000 vol	191,333
Filed 2021-10-13 17:18 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-12,000 vol	50,667
Filed 2021-10-13 17:14 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+12,000 vol	131,135
Filed 2021-10-13 17:13 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-12,000 vol	50,667
Filed 2021-10-13 17:10 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+12,000 vol	397,027
Filed 2021-10-13 17:08 Tx date 2021-10-04	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-12,000 vol	50,667
Filed 2021-08-05 18:10 Tx date 2021-08-05	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$14,864 +17,343 vol $0.86 each	27,147
Filed 2021-08-05 18:06 Tx date 2021-08-05	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,240 +3,000 vol $1.08 each	47,000
Filed 2021-08-05 18:05 Tx date 2021-08-05	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$7,420 +7,000 vol $1.06 each	44,000
Filed 2021-08-05 18:02 Tx date 2021-08-04	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$12,750 +12,500 vol $1.02 each	776,296
Filed 2021-08-05 17:58 Tx date 2021-08-04	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$10,712 +10,300 vol $1.04 each	1,871,076
Filed 2021-07-15 20:20 Tx date 2021-07-14	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$8,892 +2,600 vol $3.42 each	37,000
Filed 2021-07-15 19:57 Tx date 2021-07-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$14,280 +4,000 vol $3.57 each	763,796
Filed 2021-07-04 17:24 Tx date 2021-06-30	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$12,985 +3,500 vol $3.71 each	34,400
Filed 2021-07-04 17:20 Tx date 2021-06-30	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$14,800 +4,000 vol $3.70 each	759,796
Filed 2021-06-06 16:28 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$182,672 +41,296 vol $4.42 each	54,193
Filed 2021-06-06 16:26 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$77,636 +17,551 vol $4.42 each	26,662
Filed 2021-06-06 16:22 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$306,889 +69,377 vol $4.42 each	119,135
Filed 2021-06-06 16:18 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$1,460,188 +330,098 vol $4.42 each	442,729
Filed 2021-06-06 16:16 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$6,620,347 +1,496,631 vol $4.42 each	1,860,776
Filed 2021-06-06 16:11 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$205,506 +46,458 vol $4.42 each	126,100
Filed 2021-06-06 16:09 Tx date 2021-06-02	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$2,637,909 +596,340 vol $4.42 each	830,796
Filed 2021-06-06 16:02 Tx date 2021-06-03	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-300,300 -75,000 vol $4.00 each	755,796
Filed 2021-06-06 15:55 Tx date 2021-06-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-400,300 -100,000 vol $4.00 each	385,027
Filed 2021-03-06 12:50 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$3,002 +583 vol $5.15 each	9,111
Filed 2021-03-06 12:48 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$7,065 +1,372 vol $5.15 each	12,897
Filed 2021-03-06 12:45 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$38,861 +7,546 vol $5.15 each	79,642
Filed 2021-03-06 12:44 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$153,171 +29,742 vol $5.15 each	234,456
Filed 2021-03-06 12:40 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$256,104 +49,729 vol $5.15 each	364,145
Filed 2021-03-06 12:39 Tx date 2021-03-03	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$56,480 +10,967 vol $5.15 each	112,631
Filed 2021-03-03 20:20 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$8,977 +1,697 vol $5.29 each	8,528
Filed 2021-03-03 20:17 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$21,128 +3,994 vol $5.29 each	11,525
Filed 2021-03-03 20:13 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$116,210 +21,968 vol $5.29 each	72,096
Filed 2021-03-03 20:12 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$457,987 +86,576 vol $5.29 each	204,714
Filed 2021-03-03 20:08 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$765,775 +144,759 vol $5.29 each	314,416
Filed 2021-03-03 20:07 Tx date 2021-03-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$168,893 +31,927 vol $5.29 each	101,664
Filed 2021-02-27 17:11 Tx date 2021-02-25	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+10,833 vol	13,650
Filed 2021-02-27 17:10 Tx date 2021-02-25	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-10,833 vol	86,167
Filed 2021-02-27 17:03 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$10,086 +1,581 vol $6.38 each	6,831
Filed 2021-02-27 17:00 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$23,739 +3,721 vol $6.38 each	7,531
Filed 2021-02-27 16:55 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$130,541 +20,461 vol $6.38 each	50,128
Filed 2021-02-27 16:54 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$514,470 +80,638 vol $6.38 each	118,138
Filed 2021-02-27 16:49 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$71,296 +11,175 vol $6.38 each	49,758
Filed 2021-02-27 16:45 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$860,215 +134,830 vol $6.38 each	169,657
Filed 2021-02-27 16:43 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$189,722 +29,737 vol $6.38 each	69,737
Filed 2021-01-15 21:39 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+35,000 vol	35,000
Filed 2021-01-15 21:39 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	McNealey, Jennifer 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 19:01 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+40,000 vol	62,667
Filed 2021-01-15 18:58 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Restricted Share Units 56 - Grant of rights	+124,700 vol	124,700
Filed 2021-01-15 18:57 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 18:55 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+484,200 vol	1,089,200
Filed 2021-01-15 18:52 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+102,700 vol	197,700
Filed 2021-01-15 18:49 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+70,000 vol	120,000
Filed 2021-01-15 18:47 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+40,000 vol	62,667
Filed 2021-01-15 18:44 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+513,200 vol	1,192,200
Filed 2021-01-15 18:41 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+40,000 vol	92,000
Filed 2021-01-15 18:37 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+35,000 vol	35,000
Filed 2021-01-15 18:36 Tx date 2020-11-24	$ATE Antibe Therapeutics Inc.	Hoffman, Robert 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 17:48 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+40,000 vol	62,667
Filed 2021-01-15 17:45 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+102,700 vol	215,700
Filed 2021-01-15 17:39 Tx date 2021-01-11	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+64,500 vol	97,000
Filed 2021-01-03 16:05 Tx date 2020-12-31	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Common Shares 57 - Exercise of rights	+2,500 vol	23,500
Filed 2021-01-03 16:04 Tx date 2020-12-31	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	-2,500 vol	5,000
Filed 2020-12-17 18:50 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-204,000 vol	22,667
Filed 2020-12-17 18:49 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-180,000 vol	20,000
Filed 2020-12-17 18:48 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 37 - Stock split or consolidation	-2,160,000 vol	240,000
Filed 2020-12-17 18:47 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-1,614,000 vol	179,333
Filed 2020-12-17 18:45 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-1,417,500 vol	157,500
Filed 2020-12-17 18:44 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-630,000 vol	70,000
Filed 2020-12-17 18:43 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 37 - Stock split or consolidation	-34,290 vol	3,810
Filed 2020-12-17 18:42 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-192,763 vol	21,418
Filed 2020-12-17 18:40 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-5,445,000 vol	605,000
Filed 2020-12-17 18:39 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-2,790,000 vol	310,000
Filed 2020-12-17 18:38 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Indirect Ownership)	Common Shares 37 - Stock split or consolidation	-360,000 vol	40,000
Filed 2020-12-17 18:37 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-313,443 vol	34,827
Filed 2020-12-17 18:35 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-855,000 vol	95,000
Filed 2020-12-17 18:34 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-594,000 vol	66,000
Filed 2020-12-17 18:33 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-47,250 vol	5,250
Filed 2020-12-17 18:31 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-450,000 vol	50,000
Filed 2020-12-17 18:30 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-88,235 vol	9,804
Filed 2020-12-17 18:28 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 37 - Stock split or consolidation	-75,000 vol	8,333
Filed 2020-12-17 18:27 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-204,000 vol	22,667
Filed 2020-12-17 18:26 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-472,500 vol	52,500
Filed 2020-12-17 18:25 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-4,365,240 vol	485,027
Filed 2020-12-17 18:23 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 37 - Stock split or consolidation	-51,750 vol	5,750
Filed 2020-12-17 18:21 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-6,111,000 vol	679,000
Filed 2020-12-17 18:20 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-3,042,185 vol	338,021
Filed 2020-12-17 18:19 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Indirect Ownership)	Common Shares 37 - Stock split or consolidation	-266,999 vol	29,667
Filed 2020-12-17 18:17 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-337,500 vol	37,500
Filed 2020-12-17 18:15 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-468,000 vol	52,000
Filed 2020-12-17 18:12 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-204,000 vol	22,667
Filed 2020-12-17 18:11 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-303,757 vol	33,751
Filed 2020-12-17 18:10 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-347,242 vol	38,583
Filed 2020-12-17 18:08 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-1,017,000 vol	113,000
Filed 2020-12-17 18:06 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 37 - Stock split or consolidation	-630,000 vol	70,000
Filed 2020-12-17 18:05 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-278,100 vol	30,900
Filed 2020-12-17 18:01 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Restricted Share Units 37 - Stock split or consolidation	-67,500 vol	7,500
Filed 2020-12-17 17:59 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 37 - Stock split or consolidation	-292,500 vol	32,500
Filed 2020-12-17 17:58 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Common Shares 37 - Stock split or consolidation	-189,000 vol	21,000
Filed 2020-12-17 17:56 Tx date 2020-12-01	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Common Shares 37 - Stock split or consolidation	-25,352 vol	2,817
Filed 2020-12-17 14:50 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+53,333 vol	1,793,333
Filed 2020-12-17 14:49 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-53,333 vol	226,667
Filed 2020-12-17 14:47 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+53,333 vol	4,850,267
Filed 2020-12-17 14:46 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-53,333 vol	226,667
Filed 2020-12-17 14:42 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+53,333 vol	385,825
Filed 2020-12-17 14:41 Tx date 2020-11-30	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-53,333 vol	226,667
Filed 2020-10-08 22:45 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	1,740,000
Filed 2020-10-08 22:43 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	280,000
Filed 2020-10-08 22:40 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	4,796,934
Filed 2020-10-08 22:38 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	280,000
Filed 2020-10-08 22:32 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	332,492
Filed 2020-10-08 22:31 Tx date 2020-10-05	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	280,000
Filed 2020-10-05 22:09 Tx date 2020-09-30	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Common Shares 57 - Exercise of rights	+25,000 vol	210,000
Filed 2020-10-05 22:07 Tx date 2020-09-30	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	-25,000 vol	75,000
Filed 2020-09-25 20:05 Tx date 2020-09-24	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$33,333 +98,039 vol $0.34 each	98,039
Filed 2020-09-25 14:50 Tx date 2020-09-24	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$17,850 +52,500 vol $0.34 each	52,500
Filed 2020-09-24 13:28 Tx date 2020-09-24	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$25,500 +75,000 vol $0.34 each	375,000
Filed 2020-09-23 15:21 Tx date 2020-09-22	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$26,455 +71,500 vol $0.37 each	348,270
Filed 2020-09-22 13:59 Tx date 2020-09-21	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$10,500 +30,000 vol $0.35 each	309,000
Filed 2020-09-22 13:48 Tx date 2020-09-21	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$10,140 +28,169 vol $0.36 each	28,169
Filed 2020-09-22 13:46 Tx date 2020-05-11	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2020-07-02 13:41 Tx date 2020-06-30	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Common Shares 57 - Exercise of rights	+25,000 vol	185,000
Filed 2020-07-02 13:39 Tx date 2020-06-30	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Restricted Share Units 57 - Exercise of rights	-25,000 vol	100,000
Filed 2020-06-15 13:03 Tx date 2020-06-11	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+500,000 vol	500,000
Filed 2020-06-06 14:41 Tx date 2020-06-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 54 - Exercise of warrants	$75,000 +500,000 vol $0.15 each	2,400,000
Filed 2020-06-06 14:40 Tx date 2020-06-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Warrants 54 - Exercise of warrants	$-75,000 -500,000 vol $0.15 each	0
Filed 2020-06-06 14:35 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$28,999 +200,000 vol $0.145 each	214,181
Filed 2020-06-06 14:34 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-29,000 -200,000 vol $0.145 each	700,000
Filed 2020-06-06 14:30 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-91,500 -150,000 vol $0.61 each	212,492
Filed 2020-06-06 14:29 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$49,500 +150,000 vol $0.33 each	362,492
Filed 2020-06-06 14:28 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 51 - Exercise of options	$-49,500 -150,000 vol $0.33 each	337,508
Filed 2020-06-06 14:24 Tx date 2020-06-02	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-32,450 -55,000 vol $0.59 each	0
Filed 2020-06-06 14:23 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-90,000 -150,000 vol $0.60 each	55,000
Filed 2020-06-06 14:21 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$49,500 +150,000 vol $0.33 each	205,000
Filed 2020-06-06 14:21 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-49,500 -150,000 vol $0.33 each	660,000
Filed 2020-06-06 14:16 Tx date 2020-06-05	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$4,950 +33,000 vol $0.15 each	279,000
Filed 2020-06-06 14:15 Tx date 2020-06-05	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-4,950 -33,000 vol $0.15 each	0
Filed 2020-06-06 14:12 Tx date 2020-06-03	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-14,640 -24,000 vol $0.61 each	246,000
Filed 2020-06-06 14:10 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-125,000 -200,000 vol $0.63 each	270,000
Filed 2020-06-06 14:09 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$21,750 +150,000 vol $0.145 each	470,000
Filed 2020-06-06 14:07 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-21,750 -150,000 vol $0.145 each	700,000
Filed 2020-06-06 13:57 Tx date 2020-06-04	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-135,000 -225,000 vol $0.60 each	300,000
Filed 2020-06-06 13:57 Tx date 2020-06-03	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-156,997.50 -259,500 vol $0.60 each	525,000
Filed 2020-06-06 13:55 Tx date 2020-06-02	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-9,300 -15,500 vol $0.60 each	784,500
Filed 2020-06-06 13:55 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-762,500 -1,250,000 vol $0.61 each	800,000
Filed 2020-06-06 13:52 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$145,000 +1,000,000 vol $0.145 each	2,050,000
Filed 2020-06-06 13:51 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$247,500 +750,000 vol $0.33 each	1,050,000
Filed 2020-06-06 13:49 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-145,000 -1,000,000 vol $0.145 each	3,380,206
Filed 2020-06-06 13:47 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-247,500 -750,000 vol $0.33 each	4,380,206
Filed 2020-06-06 13:39 Tx date 2020-06-04	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Indirect Ownership)	Common Shares 10 - Acquisition or disposition in the public market	$-77,100 -128,500 vol $0.60 each	400,000
Filed 2020-06-06 13:37 Tx date 2020-06-02	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Indirect Ownership)	Common Shares 10 - Acquisition or disposition in the public market	$-57,900 -96,500 vol $0.60 each	528,500
Filed 2020-06-06 13:34 Tx date 2020-06-04	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-405,000 -675,000 vol $0.60 each	276,770
Filed 2020-06-06 13:33 Tx date 2020-06-02	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-105,000 -175,000 vol $0.60 each	951,770
Filed 2020-06-06 13:31 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-990,000 -1,650,000 vol $0.60 each	1,126,770
Filed 2020-06-06 13:28 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$181,250 +1,250,000 vol $0.145 each	2,776,770
Filed 2020-06-06 13:27 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$28,000 +200,000 vol $0.14 each	1,526,770
Filed 2020-06-06 13:26 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$346,500 +1,050,000 vol $0.33 each	1,326,770
Filed 2020-06-06 13:23 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-181,250 -1,250,000 vol $0.145 each	3,100,000
Filed 2020-06-06 13:21 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-28,000 -200,000 vol $0.14 each	4,350,000
Filed 2020-06-06 13:20 Tx date 2020-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-346,500 -1,050,000 vol $0.33 each	4,550,000
Filed 2020-05-19 21:32 Tx date 2020-05-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2020-05-19 21:32 Tx date 2020-05-01	$ATE Antibe Therapeutics Inc.	Stauffer, Joseph 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2020-05-19 17:24 Tx date 2020-05-11	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Restricted Share Units 00 - Opening Balance-Initial SEDI Report		125,000
Filed 2020-05-19 17:22 Tx date 2020-05-11	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report		325,000
Filed 2020-05-19 17:18 Tx date 2020-05-11	$ATE Antibe Therapeutics Inc.	Batal, Rami 5 - Senior Officer of Issuer Holder: 2107197 Ontario Inc (Indirect Ownership)	Common Shares 00 - Opening Balance-Initial SEDI Report		160,000
Filed 2019-11-28 13:32 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+400,000 vol	950,000
Filed 2019-11-28 13:29 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+400,000 vol	1,130,000
Filed 2019-11-28 13:26 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+475,000 vol	1,575,000
Filed 2019-11-28 13:23 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+1,850,000 vol	6,050,000
Filed 2019-11-28 13:19 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+2,040,000 vol	6,790,000
Filed 2019-11-28 13:16 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+160,000 vol	400,000
Filed 2019-11-28 13:12 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+160,000 vol	520,000
Filed 2019-11-28 13:06 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+160,000 vol	400,000
Filed 2019-11-28 12:56 Tx date 2019-11-28	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 56 - Grant of rights	+160,000 vol	400,000
Filed 2019-11-06 12:36 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Brouard, Éric Stéphane 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 57 - Exercise of rights	$22,749 +58,333 vol $0.39 each	58,333
Filed 2019-11-06 12:34 Tx date 2018-10-22	$ATE Antibe Therapeutics Inc.	Brouard, Éric Stéphane 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2019-11-06 12:21 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Brouard, Éric Stéphane 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 57 - Exercise of rights	-58,333 vol	116,667
Filed 2019-10-29 12:07 Tx date 2019-10-24	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-53,400 -120,000 vol $0.445 each	212,492
Filed 2019-10-18 12:19 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 57 - Exercise of rights	+66,667 vol	4,339,187
Filed 2019-10-18 12:18 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 57 - Exercise of rights	-66,667 vol	533,333
Filed 2019-10-18 12:06 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 57 - Exercise of rights	+66,667 vol	4,339,187
Filed 2019-10-18 12:04 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 57 - Exercise of rights	-66,667 vol	533,333
Filed 2019-10-10 16:06 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	1,620,000
Filed 2019-10-10 16:05 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	240,000
Filed 2019-10-10 16:01 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	4,676,934
Filed 2019-10-10 15:59 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	240,000
Filed 2019-10-10 15:53 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 57 - Exercise of rights	+120,000 vol	332,492
Filed 2019-10-10 15:50 Tx date 2019-10-03	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 57 - Exercise of rights	-120,000 vol	240,000
Filed 2019-09-17 12:25 Tx date 2019-09-16	$ATE Antibe Therapeutics Inc.	Binnie, Craig 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:24 Tx date 2019-09-16	$ATE Antibe Therapeutics Inc.	Binnie, Craig 5 - Senior Officer of Issuer Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:23 Tx date 2019-09-16	$ATE Antibe Therapeutics Inc.	Binnie, Craig 5 - Senior Officer of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:21 Tx date 2019-09-16	$ATE Antibe Therapeutics Inc.	Binnie, Craig 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2019-08-14 14:09 Tx date 2019-08-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 15 - Acquisition or disposition under a prospectus	$5,250 +17,500 vol $0.30 each	57,500
Filed 2019-08-14 14:07 Tx date 2019-08-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 15 - Acquisition or disposition under a prospectus	$10,500 +35,000 vol $0.30 each	300,000
Filed 2019-08-13 14:31 Tx date 2019-08-13	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 15 - Acquisition or disposition under a prospectus	$24,999 +83,333 vol $0.30 each	83,333
Filed 2019-08-13 14:25 Tx date 2019-08-13	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 15 - Acquisition or disposition under a prospectus	$50,000 +166,667 vol $0.30 each	4,556,934
Filed 2019-06-03 12:42 Tx date 2019-06-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Warrants 55 - Expiration of warrants	-300,000 vol	0
Filed 2019-06-03 12:30 Tx date 2019-06-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Warrants 55 - Expiration of warrants	-180,000 vol	0
Filed 2019-06-03 12:18 Tx date 2019-06-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-120,000 vol	0
Filed 2019-05-17 12:23 Tx date 2019-05-17	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$7,000 +20,000 vol $0.35 each	320,000
Filed 2019-05-16 16:20 Tx date 2019-05-14	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,400 +10,000 vol $0.34 each	276,770
Filed 2019-05-13 15:17 Tx date 2019-05-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$11,900 +35,000 vol $0.34 each	265,000
Filed 2019-02-27 Tx date 2019-02-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 15 - Acquisition or disposition under a prospectus	$20,000 +80,000 vol $0.25 each	230,000
Filed 2019-02-27 Tx date 2019-02-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 15 - Acquisition or disposition under a prospectus	$10,000 +40,000 vol $0.25 each	40,000
Filed 2019-02-27 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2018-12-13 Tx date 2018-12-13	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 54 - Exercise of warrants	$66,000 +300,000 vol $0.22 each	1,900,000
Filed 2018-12-13 Tx date 2018-12-13	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Warrants 54 - Exercise of warrants	$-66,000 -300,000 vol $0.22 each	500,000
Filed 2018-11-28 Tx date 2018-11-27	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$12,500 +50,000 vol $0.25 each	150,000
Filed 2018-10-24 Tx date 2018-10-22	$ATE Antibe Therapeutics Inc.	Brouard, Éric Stéphane 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report		79,000
Filed 2018-10-24 Tx date 2018-10-22	$ATE Antibe Therapeutics Inc.	Brouard, Éric Stéphane 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report		175,000
Filed 2018-10-11 Tx date 2018-10-10	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$18,700 +55,000 vol $0.34 each	55,000
Filed 2018-10-05 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 97 - Other	+4,750,000 vol	4,750,000
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 97 - Other	+360,000 vol	360,000
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 97 - Other	+4,200,000 vol	4,200,000
Filed 2018-10-05 Tx date 2016-01-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 97 - Other	+360,000 vol	360,000
Filed 2018-10-05 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 97 - Other	+600,000 vol	600,000
Filed 2018-10-05 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 97 - Other	+550,000 vol	550,000
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Restricted Share Units 97 - Other	+600,000 vol	600,000
Filed 2018-10-05 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 97 - Other	+360,000 vol	360,000
Filed 2018-10-05 Tx date 2018-03-19	$ATE Antibe Therapeutics Inc.	Khouri, Amal 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Restricted Share Units 97 - Other	+360,000 vol	360,000
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 97 - Other	+730,000 vol	730,000
Filed 2018-10-05 Tx date 2018-10-03	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Restricted Share Units 97 - Other	+1,100,000 vol	1,100,000
Filed 2018-10-05 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Restricted Share Units 00 - Opening Balance-Initial SEDI Report
Filed 2018-10-02 Tx date 2018-09-28	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$51,000 +150,000 vol $0.34 each	4,390,267
Filed 2018-09-24 Tx date 2018-09-24	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$30,819 +100,000 vol $0.3082 each	4,272,520
Filed 2018-09-20 Tx date 2018-09-19	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$27,000 +100,000 vol $0.27 each	266,770
Filed 2018-09-19 Tx date 2018-09-18	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$13,000 +50,000 vol $0.26 each	300,000
Filed 2018-09-19 Tx date 2018-09-19	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 10 - Acquisition or disposition in the public market	$9,450 +35,000 vol $0.27 each	38,100
Filed 2018-09-19 Tx date 2018-09-19	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$26,000 +100,000 vol $0.26 each	100,000
Filed 2018-09-18 Tx date 2018-09-18	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$26,170 +100,000 vol $0.2617 each	4,272,520
Filed 2018-06-10 Tx date 2018-06-07	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Common Shares 54 - Exercise of warrants	$7,500 +50,000 vol $0.15 each	210,000
Filed 2018-06-10 Tx date 2018-06-07	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Warrants 54 - Exercise of warrants	$-7,500 -50,000 vol $0.15 each	0
Filed 2018-06-10 Tx date 2018-06-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-75,000 -500,000 vol $0.15 each	0
Filed 2018-06-10 Tx date 2018-06-05	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$75,000 +500,000 vol $0.15 each	1,500,000
Filed 2018-05-02 Tx date 2018-05-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-71,820 -189,000 vol $0.38 each	166,770
Filed 2018-04-28 Tx date 2018-04-26	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-96,965 -236,500 vol $0.41 each	430,270
Filed 2018-04-28 Tx date 2018-04-27	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-30,545 -74,500 vol $0.41 each	355,770
Filed 2018-04-28 Tx date 2018-04-24	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-27,930 -66,500 vol $0.42 each	-66,500
Filed 2018-04-28 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2018-04-28 Tx date 2018-04-24	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-70,930 -173,000 vol $0.41 each	-239,500
Filed 2018-04-28 Tx date 2018-04-24	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-26,932.50 -66,500 vol $0.405 each	-306,000
Filed 2018-04-28 Tx date 2018-04-24	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-9,600 -24,000 vol $0.40 each	-330,000
Filed 2018-04-28 Tx date 2018-04-26	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-47,850 -330,000 vol $0.145 each	810,000
Filed 2018-04-28 Tx date 2018-04-26	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$47,850 +330,000 vol $0.145 each	0
Filed 2018-04-26 Tx date 2018-04-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-12,397.50 -28,500 vol $0.435 each	-588,000
Filed 2018-04-26 Tx date 2018-04-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$87,000 +600,000 vol $0.145 each	0
Filed 2018-04-26 Tx date 2018-04-20	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Indirect Ownership)	Common Shares 10 - Acquisition or disposition in the public market	$-118,575 -255,000 vol $0.465 each	296,666
Filed 2018-04-26 Tx date 2018-04-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-87,000 -600,000 vol $0.145 each	5,130,206
Filed 2018-04-26 Tx date 2018-04-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-101,015 -227,000 vol $0.445 each	-227,000
Filed 2018-04-26 Tx date 2018-04-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-146,300 -332,500 vol $0.44 each	-559,500
Filed 2018-04-26 Tx date 2018-04-23	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-5,160 -12,000 vol $0.43 each	-600,000
Filed 2018-04-20 Tx date 2018-04-19	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$27,186 +187,492 vol $0.145 each	212,492
Filed 2018-04-20 Tx date 2018-04-19	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-72,500 -500,000 vol $0.145 each	5,600,000
Filed 2018-04-20 Tx date 2018-04-19	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$72,500 +500,000 vol $0.145 each	666,770
Filed 2018-04-20 Tx date 2018-04-19	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 51 - Exercise of options	$-27,186.34 -187,492 vol $0.145 each	487,508
Filed 2018-04-17 Tx date 2018-04-17	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-74,750.40 -155,730 vol $0.48 each	166,770
Filed 2018-04-15 Tx date 2018-04-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 51 - Exercise of options	$-89,870.13 -619,794 vol $0.145 each	5,730,206
Filed 2018-04-15 Tx date 2018-04-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 51 - Exercise of options	$89,870 +619,794 vol $0.145 each	0
Filed 2018-04-14 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2018-04-14 Tx date 2018-04-11	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-217,500 -435,000 vol $0.50 each	-435,000
Filed 2018-04-14 Tx date 2018-04-12	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 40 - Short sale	$-90,549.06 -184,794 vol $0.49 each	-619,794
Filed 2018-04-11 Tx date 2018-04-10	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Indirect Ownership)	Common Shares 10 - Acquisition or disposition in the public market	$-50,000 -100,000 vol $0.50 each	625,000
Filed 2018-03-29 Tx date 2018-03-27	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-7,500 -50,000 vol $0.15 each	0
Filed 2018-03-29 Tx date 2018-03-27	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$7,500 +50,000 vol $0.15 each	322,500
Filed 2018-03-26 Tx date 2018-03-23	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-11,000 -50,000 vol $0.22 each	33,000
Filed 2018-03-26 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report		30,000
Filed 2018-03-26 Tx date 2018-03-23	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$171,750 +1,145,000 vol $0.15 each	4,240,267
Filed 2018-03-26 Tx date 2016-06-20	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Warrants 16 - Acquisition or disposition under a prospectus exemption	$7,500 +50,000 vol $0.15 each	80,000
Filed 2018-03-26 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Warrants 55 - Expiration of warrants	$-20,100 -30,000 vol $0.67 each	50,000
Filed 2018-03-26 Tx date 2018-03-22	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-164,254.50 -310,500 vol $0.53 each	4,172,520
Filed 2018-03-26 Tx date 2018-03-21	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-100,245.50 -189,500 vol $0.53 each	4,483,020
Filed 2018-03-26 Tx date 2018-03-23	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-171,750 -1,145,000 vol $0.15 each	120,000
Filed 2018-03-26 Tx date 2018-03-23	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$11,000 +50,000 vol $0.22 each	250,000
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Warrants 55 - Expiration of warrants	-75,000 vol	180,000
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-75,000 vol	50,000
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Warrants 55 - Expiration of warrants	-75,000 vol
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-75,000 vol
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-150,000 vol	1,265,000
Filed 2018-03-25 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-150,000 vol
Filed 2018-03-24 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-42,240 -66,000 vol $0.64 each	200,000
Filed 2018-03-24 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-16,250 -25,000 vol $0.65 each	241,000
Filed 2018-03-24 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	-91,000 vol
Filed 2018-03-23 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-150,000 vol	1,265,000
Filed 2018-03-23 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	-75,000 vol	50,000
Filed 2018-03-23 Tx date 2017-12-01	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Warrants 55 - Expiration of warrants	-75,000 vol	180,000
Filed 2018-03-23 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 54 - Exercise of warrants	$-3,750 -25,000 vol $0.15 each	83,000
Filed 2018-03-23 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 54 - Exercise of warrants	$3,750 +25,000 vol $0.15 each	200,000
Filed 2018-03-23 Tx date 2018-03-20	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	-91,000 vol	175,000
Filed 2018-03-22 Tx date 2018-03-21	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$-265,000 -500,000 vol $0.53 each	4,172,520
Filed 2017-09-12 Tx date 2017-09-08	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: Raging Boar Enterprises (Indirect Ownership)	Warrants 90 - Change in the nature of ownership	-500,000 vol	0
Filed 2017-09-12 Tx date 2017-09-08	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Warrants 90 - Change in the nature of ownership	+500,000 vol	500,000
Filed 2017-09-12 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2017-09-12 Tx date 2017-09-08	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: Raging Boar Enterprises (Indirect Ownership)	Common Shares 90 - Change in the nature of ownership	-1,000,000 vol	0
Filed 2017-09-12 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2017-09-12 Tx date 2017-09-08	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 90 - Change in the nature of ownership	+1,000,000 vol	1,000,000
Filed 2017-08-21 Tx date 2017-08-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 15 - Acquisition or disposition under a prospectus	$100,000 +1,000,000 vol $0.10 each	1,600,000
Filed 2017-08-21 Tx date 2017-08-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Warrants 15 - Acquisition or disposition under a prospectus	$50,000 +500,000 vol $0.10 each	800,000
Filed 2017-07-19 Tx date 2017-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Warrants 22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition	+300,000 vol	300,000
Filed 2017-07-19 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2017-07-19 Tx date 2017-07-11	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Common Shares 22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition	+600,000 vol	600,000
Filed 2017-07-19 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: NFQ Ventures Ltd (Indirect Ownership)	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2017-06-24 Tx date 2017-06-21	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 15 - Acquisition or disposition under a prospectus	$6,600 +66,000 vol $0.10 each	266,000
Filed 2017-06-24 Tx date 2017-06-21	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 15 - Acquisition or disposition under a prospectus	$3,300 +33,000 vol $0.10 each	108,000
Filed 2017-04-04 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2017-04-04 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Tritthardt, Uwe Heinrich 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 50 - Grant of options	$100,000 +500,000 vol $0.20 each	500,000
Filed 2017-04-04 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Tritthardt, Uwe Heinrich 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2017-04-04 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 50 - Grant of options	$100,000 +500,000 vol $0.20 each	500,000
Filed 2017-04-04 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2017-04-04 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Options 50 - Grant of options	$100,000 +500,000 vol $0.20 each	500,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$40,000 +200,000 vol $0.20 each	525,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$520,000 +2,600,000 vol $0.20 each	6,350,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$40,000 +200,000 vol $0.20 each	675,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$80,000 +400,000 vol $0.20 each	850,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$40,000 +200,000 vol $0.20 each	200,000
Filed 2017-04-03 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$120,000 +600,000 vol $0.20 each	900,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$460,000 +2,300,000 vol $0.20 each	6,100,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$60,000 +300,000 vol $0.20 each	1,140,000
Filed 2017-04-03 Tx date 2017-03-31	$ATE Antibe Therapeutics Inc.	Sakhia, Samira 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$40,000 +200,000 vol $0.20 each	575,000
Filed 2016-12-16 Tx date 2016-12-15	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$15,000 +100,000 vol $0.15 each	200,000
Filed 2016-12-16 Tx date 2016-12-15	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 16 - Acquisition or disposition under a prospectus exemption	$7,500 +50,000 vol $0.15 each	75,000
Filed 2016-08-15 Tx date 2016-06-20	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$10,000 +100,000 vol $0.10 each	160,000
Filed 2016-08-15 Tx date 2013-06-10	$ATE Antibe Therapeutics Inc.	Buret, Andre Gerald 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		60,000
Filed 2016-07-21 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: Raging Boar Enterprises (Indirect Ownership)	Common Shares 00 - Opening Balance-Initial SEDI Report		1,000,000
Filed 2016-07-21 Tx date 2016-07-18	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Holder: Raging Boar Enterprises (Indirect Ownership)	Warrants 00 - Opening Balance-Initial SEDI Report		500,000
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 16 - Acquisition or disposition under a prospectus exemption	$2,500 +25,000 vol $0.10 each	25,000
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Warrants 16 - Acquisition or disposition under a prospectus exemption	$50,000 +500,000 vol $0.10 each	1,415,000
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$10,000 +100,000 vol $0.10 each	272,500
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Warrants 16 - Acquisition or disposition under a prospectus exemption	$5,000 +50,000 vol $0.10 each	125,000
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$5,000 +50,000 vol $0.10 each	100,000
Filed 2016-06-14 Tx date 2016-06-10	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 16 - Acquisition or disposition under a prospectus exemption	$100,000 +1,000,000 vol $0.10 each	3,095,267
Filed 2016-03-29 Tx date 2016-03-28	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,965 +30,500 vol $0.13 each	30,500
Filed 2016-03-29 Tx date 2016-03-29	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$2,535 +19,500 vol $0.13 each	50,000
Filed 2016-03-11 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Indirect Ownership)	Common Shares 00 - Opening Balance-Initial SEDI Report		3,100
Filed 2016-03-11 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$65,249 +450,000 vol $0.145 each	450,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Flower, Roderick John 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$36,250 +250,000 vol $0.145 each	475,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$355,250 +2,450,000 vol $0.145 each	3,750,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$36,250 +250,000 vol $0.145 each	325,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Sakhia, Samira 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$36,250 +250,000 vol $0.145 each	375,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$65,249 +450,000 vol $0.145 each	840,000
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$319,000 +2,200,000 vol $0.145 each	3,800,000
Filed 2016-03-11 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		14,181
Filed 2016-03-11 Tx date 2015-12-01	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2016-03-11 Tx date 2016-03-09	$ATE Antibe Therapeutics Inc.	Wilson, Alain 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$43,500 +300,000 vol $0.145 each	300,000
Filed 2016-03-10 Tx date 2016-01-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Warrants 00 - Opening Balance-Initial SEDI Report
Filed 2016-03-10 Tx date 2016-01-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Options 00 - Opening Balance-Initial SEDI Report
Filed 2016-03-10 Tx date 2016-01-01	$ATE Antibe Therapeutics Inc.	Curtis, Scott Wilson 5 - Senior Officer of Issuer Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report
Filed 2016-02-03 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Clokie, Cameron Malcolm Lang 3 - 10% Security Holder of Issuer Holder: Urist Regenerative Med Inc. (Indirect Ownership)	Common Shares 00 - Opening Balance-Initial SEDI Report		10,043,841
Filed 2015-10-19 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Tritthardt, Uwe Heinrich 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		4,672,520
Filed 2015-10-19 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Bourgeois, Nicolas 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		4,672,520
Filed 2015-10-19 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	Fish, James 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		4,672,520
Filed 2015-10-19 Tx date 2015-10-15	$ATE Antibe Therapeutics Inc.	McMillan, Michael 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) Direct Ownership	Common Shares 00 - Opening Balance-Initial SEDI Report		4,672,520
Filed 2015-08-05 Tx date 2015-08-05	$ATE Antibe Therapeutics Inc.	Bumby, Michael Scott 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-475,000 vol	0
Filed 2015-07-24 Tx date 2015-07-13	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$28,000 +200,000 vol $0.14 each	1,300,000
Filed 2015-07-24 Tx date 2015-07-13	$ATE Antibe Therapeutics Inc.	Sakhia, Samira 4 - Director of Issuer Direct Ownership	Options 50 - Grant of options	$7,000 +50,000 vol $0.14 each	125,000
Filed 2015-07-24 Tx date 2015-07-13	$ATE Antibe Therapeutics Inc.	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$21,000 +150,000 vol $0.14 each	390,000
Filed 2015-07-24 Tx date 2015-07-13	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$28,000 +200,000 vol $0.14 each	1,600,000
Filed 2015-07-24 Tx date 2015-05-05	$ATE Antibe Therapeutics Inc.	Grushcow, Jeremy 5 - Senior Officer of Issuer Direct Ownership	Common Shares 46 - Compensation for services	$34,999 +148,936 vol $0.235 each	188,754
Filed 2015-07-24 Tx date 2015-07-24	$ATE Antibe Therapeutics Inc.	Grushcow, Jeremy 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	$-13,750 -25,000 vol $0.55 each	210,000
Filed 2015-07-24 Tx date 2015-07-24	$ATE Antibe Therapeutics Inc.	Grushcow, Jeremy 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	$-88,500 -150,000 vol $0.59 each	60,000
Filed 2015-07-24 Tx date 2015-07-24	$ATE Antibe Therapeutics Inc.	Grushcow, Jeremy 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	$-23,100 -35,000 vol $0.66 each	0
Filed 2015-07-24 Tx date 2015-07-24	$ATE Antibe Therapeutics Inc.	Grushcow, Jeremy 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	$-13,500 -25,000 vol $0.54 each	35,000